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Abstract As genetically engineered mutant mice deficient in
singlegenes are usually generated ona C57BL/6background,
to study mast cell trafficking in mutant mice, we initially
investigated whether mast cells accumulated in bronchi in
C57BL/6 mice challenged with OVA allergen acutely or
chronically for 1 to 3 months. The total number of bronchial
mast cells were quantitated using toluidine blue staining in
airways of different sizes, i.e. , small (<90 µm), medium (90–
155 µm), or large (>150 µm) airways. Non-OVA challenged
and acute OVA challenged mice (C57BL/6 and BALB/c) had
no detectable bronchial mast cells. Chronic OVA challenge in
BALB/cmice for 1 or 3 months induced a significant increase
in the number of bronchial mast cells in small-, medium-, and
large-sized airways but minimal change in the number of
bronchial mast cells in C57BL/6 mice. Both BALB/c and
C57BL/6 mice developed significant lung eosinophilia
following acute or chronic OVA challenge. Studies of IL-9-
deficient mice on a BALB/c background demonstrated a
significant increase in the number of bronchial mast cells in
IL-9-deficient mice suggesting that IL-9 was not required for
the bronchial accumulation of mast cells. Overall, these
studies demonstrate that the chronic OVA challenge protocol
we have utilized in BALB/c mice provides a model to study
the mechanism of bronchial mast cell accumulation and that
bronchial mast cell accumulation in chronic OVA challenged
mice is independent of IL-9 in this model.
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Introduction
Studies in mouse models of asthma (Kobayashi et al. 2000;
Martin et al. 1993), as well as in human asthmatics (Black
2002;B r a d d i n ge ta l .2006), have suggested an important
role for mast cells in the pathogenesis of asthma. For
example, studies in human asthmatics have demonstrated
that the early phase response to inhalation of allergen is
associated with increased levels of mast cell-derived medi-
ators such as histamine and that this early phase response can
be blocked with mast cell-directed antagonists such as
antihistamines, or anti-IgE (Barrett and Austen 2009;
Bradding et al. 2006; Brown et al. 2008; Galli et al. 2008,
Milgrom et al. 1999). In addition to this evidence of mast cell
involvement in human allergen challenge models of asthma,
there is also evidence in spontaneous chronic asthma of
ongoing mast cell degranulation (Broide et al. 1991), as well
as evidence that mast cell-directed therapies such as anti-IgE
reduce asthma exacerbations and allow for reductions by
asthmatics of corticosteroid use (Milgrom et al. 1999).
Studies in mouse models of asthma using mutant mice
deficient in mast cells have also provided evidence for an
important role for mast cells in airway hyperreactivity
(Kobayashi et al. 2000;M a r t i ne ta l .1993), eosinophilic
airway inflammation (Williams and Galli 2000), and airway
remodeling (Yu et al. 2006). Special low-dose allergen
sensitization protocols without adjuvant need to be utilized
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models (Williams and Galli 2000;Y ue ta l .2006)b e c a u s eo f
the small numbers of mast cells in the murine lung compared
to the human lung. We have demonstrated that chronic
inhalation OVA allergen challenge induces the recruitment of
significant numbers of mast cells to the bronchial region in
BALB/c mice and that this accumulation of bronchial mast
cells is significantly reduced in BALB/c mice pretreated with
a TLR-9 agonist (Ikeda et al. 2003). As studies of mutant
mice deficient in single genes provide an important tool to
dissect the role of individual genes in contributing to
accumulation of bronchial mast cells, in this study, we
investigated whether bronchial mast cells accumulate in
C57BL/6 mice (a common background strain of gene
targeted mice) and then used IL-9-deficient mice to explore
the role of IL-9, a cytokine associated with mast cell
proliferation (Godfraind et al. 2009;T e m a n ne ta l .1988;
Townsend et al. 2000) in contributing to bronchial mast cell
accumulation following chronic OVA challenge for up to
3m o n t h s .
Materials and methods
Induction of bronchial accumulation of mast cells
The mouse model of OVA-induced accumulation of bronchial
mastcellshaspreviouslybeendescribed(Ikedaetal.2003). In
brief, 8- to 10-week-old female BALB/c mice (n=8/group;
Jackson Laboratory, Bar Harbor, ME, USA), C57BL/6 mice
(n=8/group; Jackson Laboratory, Bar Harbor, ME, USA), or
IL-9-deficient mice on a BALB/c background (kindly
provided by Dr A McKenzie, UK; Townsend et al. 2000;
n=8 mice/group) were immunized sc on days 0, 7, 14, and
21 with 25 μg of OVA (grade V, Sigma) adsorbed to 1 mg of
alum (Aldrich) in 200 μl of normal saline. For the acute OVA
protocol, intranasal OVA challenges (20 μg/50 μli nP B S )
were administered on days 27, 29, and 31 under isoflurane
(Vedco, St. Joseph, MO, USA) anesthesia, and mice were
sacrificed 24 h later. LPS levels in the 20 μgo fO V A
administered intranasally were 1.4 ng as measured by limulus
amebocyte lysate assay according the manufacturer instruc-
tions (Lonza, Walkersville, MD, USA; sensitivity of LPS
assay 0.01 ng/ml). For the chronic OVA protocol, mice were
sensitized and challenged intranasally as described for the 31-
day acute OVA protocol. Intranasal OVA challenges were
then repeated twice a week for 1 to 3 months. Age- and sex-
matched control mice were sensitized but not challenged with
OVA during the study. Mice were sacrificed 24 h after the
final acute or chronic OVA challenge and bronchoalveolar
lavage (BAL) fluid was collected by lavaging the lung with
1 mL PBS via a tracheal catheter (Ikeda et al. 2003). Lungs
from the different experimental groups were processed as a
batch for toluidine blue staining under identical conditions.
Stained slides were all quantified under identical light
microscope conditions, including magnification (×20), gain,
camera position, and background illumination. All animal
experimental protocols were approved by the University of
California, San Diego Animal Subjects Committee.
Toluidine blue staining and quantitation of bronchial
mast cells
Quantitation of bronchial mast cells was performed as
previously described in this laboratory on formalin-fixed
paraffin-embedded lungs (Ikeda et al. 2003). In brief, the
paraffin-embedded lungs were sectioned at 5 μmo n t o
microscope slides, and the paraffin was removed using
alcohol gradients and Citrosolv (Fisher, Pittsburgh, PA,
USA). The lung sections were stained with 1% toluidine
blue (Sigma-Aldrich) to detect metachromatic mast cell
cytoplasmic granules as previously described in this
laboratory (Ikeda et al. 2003). Light microscopy was used
to count the number of mast cells per airway in lung
sections. To standardize the quantification of bronchial
mast cells, airways were characterized by size using a light
microscope (Leica DMLS, Leica Microsystems) attached
to an image analysis system (Image-Pro plus, Media
Cybernetics) as large (125–250 μm), medium (60–
125 μm), or small (<60 μm) by measuring the diameter
of the long axis of the airway as previously described
(Ikeda et al. 2003). The bronchial area was defined as the
circumferential area extending from the lumenal surface of
the airway epithelium to 8 μm beneath the basement
membrane of the airway epithelium in small airways, to
15 μm beneath the basement membrane of the airway
epithelium in medium-sized airways, and to 20 μm
beneath the basement membrane of the airway epithelium
in large airways (Ikeda et al. 2003). The distance beneath
the basement membrane chosen to define the bronchial
space was based on pilot experiments demonstrating the
area in which the majority of nonmast cell bronchial
inflammatory cells were recruited after OVA allergen
challenge. The number of mast cells per airway was
counted in ten randomly selected airways of each size in
each mouse. In selected experiments, we used immuno-
histochemistry on lung sections as previously described in
this laboratory (Ikeda et al. 2003) to detect the mouse
mucosal mast cell granule protease mMCP-1 with an anti-
mMCP-1 Ab (Pemberton et al. 2003). A species and
isotype control Ab was used in these experiments.
Statistical analysis
Data were collected and analyzed with T tests using Prism
statistical software. Values of p<0.05 were considered
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Results
Mast cells accumulate following 1 month of chronic OVA
antigen challenge in small, medium, and large airways
of BALB/c but not C57BL/6 mice
Bronchial mast cells were not detected in non-OVA-
challenged mice in small, medium, or large airways in
either BALB/c or C57BL/6 mice by toluidine blue staining
or immunostaining with an anti-mMCP-1 Ab (Fig. 1).
However, in BALB/c mice subjected to 1 month of chronic
OVA challenge, significantly increased numbers of mast
cells were detected compared to non-OVA-challenged
BALB/c mice in small airways (0.7±0.7 vs 0±0 mast
cells/airway; p=0.03) (Fig. 2a), medium-sized airways
(1.3±0.5 vs 0±0 mast cells/airway; p<0.0001; Fig. 2b),
and large-sized airways (1.0±0.5 vs 0±0 mast cells/airway;
p=0.0003; Fig. 2c). As previously reported (Ikeda et al.
2003), the majority of bronchial mast cells in chronic OVA
challenged mice were intraepithelial (>95%; Fig. 1b, d).
Immunostaining with an anti-mMCP-1 Ab demonstrated
similar numbers of mMCP-1-positive and toluidine blue-
positive mast cells in lung sections, as well as a similar
distribution of toluidine blue-positive cells and mMCP-1-
positive cells in airway epithelium (Fig. 1). In contrast to
chronically OVA-challenged BALB/c mice which accumu-
lated bronchial mast cells in response to chronic OVA
challenge for 1 month, chronic OVA-challenged C57BL
mice did not accumulate any mast cells at 1 month in either
small airways (0±0 mast cells/airway; Fig. 2a), medium-
sized airways (0±0 mast cell/airway; Fig. 2b), or large-
sized airways (0±0 mast cells/airway; Fig. 2c).
Chronic OVA challenge for 3 months induces further
increase in mast cell accumulation in small-, medium-,
and large-sized airways of BALB/c but not C57BL/6 mice
BALB/c mice subjected to 3 months of chronic OVA
challenge had increased numbers of mast cells com-
pared to 1 month chronic OVA-challenged BALB/c
a a b b
c c d d
Toluidine
mMCP-1 
BALB/c No OVA (For 3months) BALB/c Chronic OVA (For 3months)
Blue
Fig. 1 Airway mast cell detection. Lung sections were stained with
toluidine blue (1%) or immunostained with an anti-mMCP-1 Ab to
detect mast cells. No toluidine blue-positive mast cells were detected
in non-OVA-challenged BALB/c mice (a), whereas several toluidine
blue-positive mast cells (arrows) were detected in the airway
epithelium in BALB/c mice chronically challenged with OVA for
3 months (b). Similarly, no mMCP-1-positive mast cells were detected
in non-OVA-challenged BALB/c mice (c), whereas several mMCP-1-
positive mast cells were detected in the airway epithelium in BALB/c
mice chronically challenged with OVA for 3 months (d)
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airway; p<0.01; Fig. 2a), medium-sized airways (2.6±
0.5 vs 1.3±0.5 mast cells/airway; p<0.01; Fig. 2b), and
large-sized airways (3.3±0.8 vs 1.0±0.5 mast cells/
airway; p<0.01; Fig. 2c). In contrast to the increased
numbers of bronchial mast cells in BALB/c mice
chronically challenged with OVA (mean of 2.0, 2.6, and
3.3 mast cells/small, medium, or large airway), C57BL/6
mice subjected to 3 months of chronic OVA challenge
had minimal bronchial mast cell accumulation, i.e. , <0.2
mast cell/airway (small airway 0.2±0.5 mast cells/airway
(Fig. 2a); medium-sized airway 0.2±0.1 mast cells/
airway (Fig. 2b); large-sized airway 0.1±0.1 mast cells/
airway; Fig. 2c).
BAL eosinophil accumulation in BALB/c and C57BL/6
mice
Non-OVA-challenged mice (either BALB/c or C57BL/6
mice) had no eosinophils in BAL (Fig. 3). In contrast, acute
OVA challenge (Fig. 3a), or chronic OVA challenge for
1 month (Fig. 3b) or 3 months (Fig. 3c), induced significant
BAL eosinophilia in both BALB/c and C57BL/6 mice. The
number of BAL eosinophils was the highest following acute
OVA challenge and decreased with chronic OVA challenge
in both BALB/c and C57BL/6 mice. The numbers of BAL
eosinophils were higher in C57BL/6 compared to BALB/c
mice challenged acutely or chronically with OVA. The acute
and chronic OVA protocols induce minimal BAL neutrophil
responses in both strains of mice (data not shown).
Studies of mast cell accumulation in IL-9-deficient mice
on a BALB/c background
As our studies demonstrated that studying mast cell
accumulation in gene-deficient mice on a C57BL/6 back-
ground would be challenging to interpret (based on the very
low levels of mast cell accumulation in C57BL/6 mice the
background strain of most gene-deficient mice), we
examined mast cell accumulation in IL-9-deficient mice
on a BALB/c background for at least 12 generations.
Acute OVA challenge (WT vs IL-9 deficient)
Bronchial mast cells were not detected in non-OVA or acute
OVA-challenged mice in either BALB/c or IL-9-deficient
mice in small (Fig. 4a), medium (Fig. 4b), or large airways
(Fig. 4c).
Chronic OVA challenge for 1 month (WT vs IL-9 deficient)
Following 1 month of chronic OVA challenges, there was a
similar significant accumulation of bronchial mast cells in
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Fig. 2 Quantitation of airway mast cells in BALB/c and C57BL/6
mice following acute and chronic OVA challenge. BALB/c or C57BL/
6 mice were challenged with OVA acutely or chronically for 1 or
3 months. Non-OVA-challenged BALB/c or C57BL/6 mice served as
controls. The number of toluidine blue-positive bronchial mast cells in
small airways (a), medium-sized airways (b), and large airways (c)
were quantitated. Acute OVA challenge induced no increase in
bronchial mast cells in BALB/c or C57BL/6 mice. Chronic OVA
challenge in BALB/c mice induced a significant increase in bronchial
mast cells at 1 month in small (p=0.03; a), medium (p<0.0001; b), as
well as large airways (p=0.0003; c). Similarly, 3 months of chronic
OVA challenge in BALB/c mice induced a significant increase in
bronchial mast cells in small (p<0.05; Fig. 2a), medium (p<0.001;
Fig. 2b), as well as large airways (p=0.003; c). In contrast, chronic
OVA challenge in C57BL/6 mice for 1 or 3 months did not increase
the number of bronchial mast cells in small (a), medium (b), or large
airways (c; n=8 mice/group)
502 Immunogenetics (2010) 62:499–506both IL-9-deficient as well as in BALB/c WT mice in the
small airways (1.1±0.3 vs 0.7±0.2 mast cells/airway;
Fig. 4a), medium-sized airways (1.0±0.3 vs 0.6±0.2 mast
cells/airway; Fig. 4b), and large airways (1.8±1.1 vs 2.0±
0.7 mast cells/airway; IL-9 KO chronic OVAvs WTchronic
OVA; Fig. 4c). There were no statistically significant
differences in mast cell accumulation in the small, medium,
or large airways between IL-9 KO vs WT mice following
1 month chronic OVA challenge.
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Fig. 3 Quantitation of BAL eosinophils in BALB/c and C57BL/6 mice
following acute and chronic OVA challenge. BALB/c or C57BL/6 mice
werechallengedwithOVAacutelyorchronicallyfor1or3months.Non-
OVA-challenged BALB/c or C57BL/6 mice served as controls. The
number of Wright Giemsa-positive eosinophils in BAL were quantitated.
Acute OVA challenge induced a significant increase in BAL eosinophils
in C57BL/6 (p<0.001) and BALB/c mice (p<0.01; a). Chronic OVA
challenge in C57BL/6 mice induced a significant increase in BAL
eosinophils at 1 month (p<0.01; b)a n da t3m o n t h s( p<0.05; c).
Similarly, in BALB/c, chronic OVA challenge induced a significant
increase in BAL eosinophils at 1 month (p<0.01; b) and at 3 months
(p<0.05; c; n=8 mice/group)
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Fig. 4 Quantitation of airway mast cells in WT and IL-9-deficient
mice following acute and chronic OVA challenge. BALB/c (referred
to as WT) or IL-9-deficient mice on a BALB/c background (referred
to as IL-9 KO) were challenged with OVA acutely or chronically for 1
or 3 months. Non-OVA-challenged WT or IL-9 KO mice served as
controls. The number of toluidine blue-positive bronchial mast cells in
small airways (a), medium-sized airways (b), and large airways (c)
were quantitated. Acute OVA challenge induced no increase in
bronchial mast cells in WT or IL-9 KO mice. There was no difference
in the number of bronchial mast cells in chronic OVA allergen-
challenged IL-9 KO compared to WT mice at 1 month in the small
airways (a), medium airways (b), or large airways (c). At 3 months,
there was also no difference in the number of bronchial mast cells in
chronic OVA allergen challenged IL-9 KO compared to WT mice in
medium-sized airways (p = ns; b), but there was an increase in the
number of mast cells in the small airways (p<0.05; a) and large
airways (p<0.01; c) of IL-9 KO mice compared to WT mice (n=
8 mice/group)
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The number of mast cells in the small airways (p=0.05)
(Fig. 4a) and large airways (p=0.01; Fig. 4b) of IL-9-
deficient mice challenged chronically with OVA allergen
for 3 months was more than that of WT mice, while a
similar number of bronchial mast cells was noted in the
medium-sized airways of IL-9-deficient and WT mice
(3.7±0.6 vs 3.5±0.8 mast cells/airway; p = ns; Fig. 4b).
Discussion
In this study, we have demonstrated that chronic allergen
challenge induces a significant accumulation of mast cells
in the bronchial region in BALB/c mice but did not induce
a similar significant increase in bronchial mast cell number
in C57BL/6 mice. Interestingly, both BALB/c and C57BL/6
mice developed significant BAL eosinophilia following
acute or chronic OVA challenge, suggesting that the
significantly reduced numbers of bronchial mast cells in
chronic OVA challenged C57BL/6 mice was not due to an
impaired response by all inflammatory cells to the chronic
OVA allergen challenge. The number of mast cells recruited
to the airway in chronic OVA-challenged C57BL/6 mice
(approximately 0.2 mast cells/hpf) is not significantly
different from that noted in non-OVA-challenged mice
(0 mast cells/hpf) and 10–15-fold less than that observed in
chronic OVA-challenged BALB/c mice (approximately 2 to
3/hpf at 3 months). Thus, performing studies of the
accumulation of bronchial mast cells in mutant mice on a
C57BL/6 background would be difficult to interpret based
on the very limited mast cell response in C57BL/6 mice to
chronic administration of allergen. To investigate whether
IL-9 contributes to the accumulation of bronchial mast cells
following chronic allergen challenge, we therefore used IL-
9-deficient mice on a BALB/c background. These studies
demonstrated that the bronchial accumulation of mast cells
in chronic OVA-allergen-challenged mice for 1 or 3 months
was IL-9 independent in small-, medium-, or large-sized
airways.
Mouse strain specific differences in airway hyperreac-
tivity and Th2 responses have been noted in models of
acute asthma (Tumes et al. 2007; Walsh et al. 2008; Zhu
and Gilmour 2009) and models of airway remodeling
(Hirota et al. 2009; Shinagawa and Kojima 2003;V a n
Hove et al. 2009). Our study extends this observation of
strain-specific differences in mouse models of asthma to
differences in the ability to recruit mast cells to the
bronchial region in BALB/c vs C57BL/6 mice in the model
of OVA-induced allergic airway inflammation tested. This
indicates that, in this asthma model, BALB/c mice are
likely to be superior to C57BL/6 mice for studies of mast
cell trafficking in gene-targeted mice. In contrast to the
increased numbers of bronchial mast cells that occurs with
time in chronic vs acute OVA models in BALB/c mice, our
studies demonstrate that BAL eosinophil responses are the
highest following acute OVA challenge and decrease with
chronic exposure in both BALB/c and C57BL/6 mice. We
have previously reported similar observations regarding
lung eosinophil responses in both BALB/c (Cho et al.
2004a) and C57BL/6 mice (Cho et al. 2004b) subjected to
chronic OVA challenge. Both C57BL/6 and BALB/c mice
develop significant airway remodeling with chronic OVA
challenge, with C57BL/6 tending to develop slightly higher
levels of airway remodeling compared to BALB/c mice
(Cho et al. 2004a, b).
Our studies alsodemonstratedthatIL-9-deficientmiceona
BALB/cbackgroundrecruitmastcellstothesmall-,medium-,
and large-sized airways as efficiently as wild-type mice. The
potential for IL-9 to be a mast cell growth factor has been
recognized in studies of IL-9 transgenic mice which have
significantly increased levels of mast cells in various tissues
including the lung (Godfraind et al. 2009; Temann et al.
1988). Studies of IL-9-deficient mice infected with schisto-
somiasis have also demonstrated the importance of IL-9 to
pulmonary mastocytosis following acute but not chronic
challenge (Townsend et al. 2000). In a model of acute OVA
challenge, the number of mast cell precursor colonies in the
digested lungs of IL-9-deficient mice on a BALB/c
background was reduced (Jones et al. 2009). Differences in
the results from these studies may relate to differences in
requirements for IL-9 in the mouse models used (i.e.,
transgenic, schistosoma antigen, acute vs chronic allergen
exposure), and differences in requirements for IL-9 depend-
ing upon the mast cells quantitated (mast cell precursor vs
mature mast cell), or differences in requirements for IL-9
depending upon the localization of the mast cell in the lung
(mast cells precursors were quantitated from whole lung
digests, whereas mature mast cells were quantitated in small,
medium, and large airways). Our study demonstrates that,
with chronic allergen challenge, bronchial mast cells can
accumulate in an IL-9-independent manner. Studies with
these IL-9-deficient mice in an acute OVA challenge asthma
model (McMillan et al. 2002)h a v ea l s od e m o n s t r a t e dt h a t
IL-9 is not required for the development of mucus,
eosinophilic inflammation, IgE, Th2 cytokines, or airway
responsiveness suggesting like in our study that other
allergen-induced mediators can act in a compensatory
fashion. Mast cells can increase in number in response to a
variety of mediators other than IL-9 which are expressed
following allergen challenge including cytokines that induce
mast cell proliferation, i.e., IL-3 (Razin et al. 1984), IL-4
(Mossman et al. 1986), stem-cell factor (Zsebo et al. 1990),
and chemokines that may recruit mast cells to the lung
(Palmqvist et al. 2007). The increased numbers of bronchial
504 Immunogenetics (2010) 62:499–506mast cells in IL-9-deficient mice following 3 months of
chronic OVA challenge could be due to compensatory
increased levels of these or other mast cell growth factors
at this time point. Further studies are needed to determine
whether neutralizing these cytokines and/or chemokines
selectively or in combination inhibits the chronic allergen
induced bronchial accumulation of mast cells.
In summary, in this study, we have demonstrated that
investigation of recruitment of mast cells to the airway in
the mouse are best studied in BALB/c mice rather than in
C57BL/6 mice. In addition, if studies of mast cell
recruitment to the lung are performed in gene-targeted
mice, the studies should be performed in mutant mice on a
BALB/c background. Using this approach with IL-9-
deficient mice on a BALB/c background, we have
demonstrated that bronchial mast cell accumulation in
chronic allergen-challenged mice is IL-9 independent
underscoring the potential utility of this model to studies
of mast cell recruitment to the airway in mutant mice on a
BALB/c background.
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